Essilor: 2012 Registration Document Filed

  Essilor: 2012 Registration Document Filed

Business Wire

CHARENTON-LE-PONT, France -- April 3, 2013

Regulatory News:

The 2012 Essilor (Paris:EI) Registration Document was filed in French version
with the Autorité des Marchés Financiers (AMF) on April 2, 2013 under the
number D.13-0252. The Registration Document includes:

a) The Annual Financial Report, with:

  *The parent company financial statements;
  *The consolidated financial statements;
  *A management report containing information in compliance with articles
    L.225-100, L.225-100-3, L.225-11 (§ 2) and L.225-100-2 of the French
    Commercial Code;
  *A statement by the persons responsible for the Registration Document;
  *The report of the Auditors on the parent company and consolidated
    financial statements;
  *Information concerning Auditors’ fees.

b) The Chairman’s report on corporate governance and internal control.

c) The description of the share buyback program.

From now on, the French version is available to the public free of charge, as
provided for in applicable legislation, and may be viewed on Essilor’s
corporate website www.essilor.com. The English version will be available in a
few days.

About Essilor

The world’s leading ophthalmic optics company, Essilor designs, manufactures
and markets a wide range of lenses to improve and protect eyesight. Its
corporate mission is to enable everyone around the world to access lenses that
meet his or her unique vision requirements. To support this mission, the
Company allocates more than €150 million to research and innovation every
year, in a commitment to continuously bring new, more effective products to
market. Essilor’s flagship brands are Varilux^®, Crizal^®, Definity^®,
Xperio^®, Optifog^TM and Foster Grant^®. It also develops and markets
equipment, instruments and services for eyecare professionals.

Essilor reported consolidated revenue of approximately €5 billion in 2012 and
employs around 50,700 people in some 100 countries. It operates 22 plants,
more than 400 prescription laboratories and edging facilities, as well as
several research and development centers around the world.

For more information, please visit www.essilor.com.

The Essilor share trades on the NYSE Euronext Paris market and is included in
the Euro Stoxx 50 and CAC 40 indices.

Codes and symbols: ISIN: FR FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.

Contact:

Investor Relations and Financial Communications
Phone: +33 (0)1 49 77 42 16